CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Standard BioTools Inc - LAB CFD

2.4437
3.82%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.0226
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Standard BioTools Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 2.3537
Open* 2.3937
1-Year Change* 26.89%
Day's Range* 2.3837 - 2.4937
52 wk Range 1.46-3.16
Average Volume (10 days) 3.46M
Average Volume (3 months) 23.30M
Market Cap 662.87M
P/E Ratio -100.00K
Shares Outstanding 289.46M
Revenue 105.17M
EPS -0.96
Dividend (Yield %) N/A
Beta 1.67
Next Earnings Date N/A

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 23, 2024 2.4437 0.1400 6.08% 2.3037 2.5037 2.3037
Feb 22, 2024 2.3537 -0.0600 -2.49% 2.4137 2.4537 2.3037
Feb 21, 2024 2.3937 -0.0600 -2.45% 2.4537 2.4537 2.3837
Feb 20, 2024 2.4837 0.0100 0.40% 2.4737 2.6237 2.4737
Feb 16, 2024 2.5537 0.1200 4.93% 2.4337 2.6137 2.4337
Feb 15, 2024 2.4837 0.1700 7.35% 2.3137 2.5237 2.3137
Feb 14, 2024 2.3337 0.1000 4.48% 2.2337 2.4137 2.2337
Feb 13, 2024 2.3137 -0.0100 -0.43% 2.3237 2.3337 2.2337
Feb 12, 2024 2.3937 0.0500 2.13% 2.3437 2.4337 2.3437
Feb 9, 2024 2.3737 0.0300 1.28% 2.3437 2.4137 2.3037
Feb 8, 2024 2.3637 0.0600 2.60% 2.3037 2.4037 2.3037
Feb 7, 2024 2.3537 -0.0300 -1.26% 2.3837 2.4137 2.3137
Feb 6, 2024 2.3837 0.0400 1.71% 2.3437 2.4037 2.3137
Feb 5, 2024 2.4137 0.0700 2.99% 2.3437 2.4937 2.3337
Feb 2, 2024 2.4137 0.1600 7.10% 2.2537 2.4237 2.2037
Feb 1, 2024 2.2737 0.0600 2.71% 2.2137 2.3137 2.1637
Jan 31, 2024 2.2537 0.0000 0.00% 2.2537 2.3537 2.2337
Jan 30, 2024 2.2937 -0.0500 -2.13% 2.3437 2.4637 2.2637
Jan 29, 2024 2.4237 0.0800 3.41% 2.3437 2.4437 2.2637
Jan 26, 2024 2.3637 0.0200 0.85% 2.3437 2.4437 2.3337

Standard BioTools Inc Events

Time (UTC) Country Event
Wednesday, February 28, 2024

Time (UTC)

21:00

Country

US

Event

Q4 2023 Standard BioTools Inc Earnings Release
Q4 2023 Standard BioTools Inc Earnings Release

Forecast

-

Previous

-

Time (UTC)

21:30

Country

US

Event

Q4 2023 Standard BioTools Inc Earnings Call
Q4 2023 Standard BioTools Inc Earnings Call

Forecast

-

Previous

-
Thursday, June 13, 2024

Time (UTC)

15:30

Country

US

Event

Standard BioTools Inc Annual Shareholders Meeting
Standard BioTools Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 97.948 130.581 138.144 117.243 112.964
Revenue 97.948 130.581 138.144 117.243 112.964
Cost of Revenue, Total 60.897 61.208 54.818 52.964 51.315
Gross Profit 37.051 69.373 83.326 64.279 61.649
Total Operating Expense 214.153 198.049 189.18 181.102 161.128
Selling/General/Admin. Expenses, Total 114.758 98.888 97.901 84.478 79.783
Research & Development 38.498 37.944 36.461 31.64 30.03
Unusual Expense (Income) 0.009 0 12.02
Operating Income -116.205 -67.468 -51.036 -63.859 -48.164
Interest Income (Expense), Net Non-Operating -64.412 -3.823 -3.572 -4.279 -13.893
Other, Net -12.311 7.631 0.507 1.433 0.637
Net Income Before Taxes -192.928 -63.66 -54.101 -66.705 -61.42
Net Income After Taxes -190.098 -59.237 -53.02 -64.79 -59.013
Net Income Before Extra. Items -190.098 -59.237 -53.02 -64.79 -59.013
Net Income -190.098 -59.237 -53.02 -64.79 -59.013
Income Available to Common Excl. Extra. Items -190.098 -59.237 -53.02 -64.79 -59.013
Income Available to Common Incl. Extra. Items -190.098 -59.237 -53.02 -64.79 -59.013
Dilution Adjustment
Diluted Net Income -190.098 -59.237 -53.02 -64.79 -59.013
Diluted Weighted Average Shares 78.305 75.786 72.044 66.779 39.652
Diluted EPS Excluding Extraordinary Items -2.42766 -0.78164 -0.73594 -0.97022 -1.48827
Diluted Normalized EPS -2.42766 -0.78156 -0.73594 -0.85322 -1.48827
Total Extraordinary Items 0
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 27.666 25.119 27.021 25.646 18.777
Revenue 27.666 25.119 27.021 25.646 18.777
Cost of Revenue, Total 14.064 12.782 15.854 16.426 14.35
Gross Profit 13.602 12.337 11.167 9.22 4.427
Total Operating Expense 45.115 41.712 48.133 54.673 57.34
Selling/General/Admin. Expenses, Total 22.6 21.295 23.902 29.597 30.084
Research & Development 6.184 6.485 8.377 8.65 9.106
Operating Income -17.449 -16.593 -21.112 -29.027 -38.563
Interest Income (Expense), Net Non-Operating -1.129 -1.117 -1.19 -1.049 -23.351
Other, Net 1.839 1.13 1.527 -0.063 -3.238
Net Income Before Taxes -16.739 -16.58 -20.775 -30.139 -65.152
Net Income After Taxes -17.04 -16.843 -20.845 -29.426 -63.539
Net Income Before Extra. Items -17.04 -16.843 -20.845 -29.426 -63.539
Net Income -17.04 -16.843 -20.845 -29.426 -63.539
Income Available to Common Excl. Extra. Items -17.04 -16.843 -20.845 -29.426 -63.539
Income Available to Common Incl. Extra. Items -17.04 -16.843 -20.845 -29.426 -63.539
Diluted Net Income -17.04 -16.843 -20.845 -29.426 -63.539
Diluted Weighted Average Shares 78.669 78.771 79.448 78.897 77.821
Diluted EPS Excluding Extraordinary Items -0.2166 -0.21382 -0.26237 -0.37297 -0.81648
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -0.19787 -0.20433 -0.26237 -0.37297 -0.78474
Unusual Expense (Income) 2.267 1.15 3.8
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 208.815 72.066 117.663 96.096 127.106
Cash and Short Term Investments 165.784 28.451 68.52 58.639 95.401
Cash 47.818 16.614 17.685
Cash & Equivalents 81.309 28.451 20.702 5.047 77.716
Short Term Investments 84.475 0 36.978 0
Total Receivables, Net 17.28 18.32 25.423 18.981 16.651
Accounts Receivable - Trade, Net 17.28 18.32 25.423 18.981 16.651
Total Inventory 21.473 20.825 19.689 13.884 13.003
Prepaid Expenses 3.263 3.454 4.031 4.592 2.051
Total Assets 390.31 275.214 324.757 264.812 303.647
Property/Plant/Equipment, Total - Net 59.535 65.153 55.645 12.916 8.825
Property/Plant/Equipment, Total - Gross 98.995 98.954 83.42 39.668 31.68
Accumulated Depreciation, Total -39.46 -33.801 -27.775 -26.752 -22.855
Goodwill, Net 106.251 106.379 106.563 104.108 104.108
Intangibles, Net 13.178 29.184 42.224 49.132 57.4
Long Term Investments
Other Long Term Assets, Total 2.531 2.432 2.662 2.56 6.208
Total Current Liabilities 43.443 49.568 54.249 32.821 37.582
Accounts Payable 7.914 10.602 9.22 6.51 4.027
Accrued Expenses 19.01 16.646 31.554 14.508 22.091
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 14.436 15.482 13.475 11.803 11.464
Total Liabilities 160.524 180.618 185.707 111.2 231.531
Total Long Term Debt 62.809 64.209 54.224 53.821 172.058
Long Term Debt 62.809 64.209 54.224 53.821 172.058
Deferred Income Tax 1.055 4.329 8.697 11.494 13.714
Other Liabilities, Total 53.217 62.512 68.537 13.064 8.177
Total Equity 229.786 94.596 139.05 153.612 72.116
Preferred Stock - Non Redeemable, Net 0 0 0 0
Common Stock 0.08 0.077 0.075 0.07 0.049
Additional Paid-In Capital 847.008 831.424 815.624 777.765 631.605
Retained Earnings (Accumulated Deficit) -926.096 -735.998 -676.761 -623.641 -558.851
Other Equity, Total -1.394 -0.907 0.112 -0.618 -0.687
Total Liabilities & Shareholders’ Equity 390.31 275.214 324.757 264.812 303.647
Total Common Shares Outstanding 79.482 76.919 74.543 69.956 49.338
Unrealized Gain (Loss) -0.502 0 0.036
Other Current Assets, Total 1.015 1.016
Current Port. of LT Debt/Capital Leases 2.083 6.838
Redeemable Preferred Stock 311.253
Treasury Stock - Common -0.563
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 170.741 183.07 194.928 208.815 229.017
Cash and Short Term Investments 128.85 142.304 154.537 165.784 185.168
Cash & Equivalents 79.655 142.304 113.663 81.309 60.2
Total Receivables, Net 16.56 15.119 14.504 17.28 17.294
Accounts Receivable - Trade, Net 16.56 15.119 14.504 17.28 17.294
Total Inventory 21.927 22.08 22.513 21.473 21.946
Prepaid Expenses 3.404 3.567 3.374 3.263 3.594
Other Current Assets, Total 1.015 1.015
Total Assets 339.285 355.827 371.654 390.31 414.915
Property/Plant/Equipment, Total - Net 55.729 56.716 57.976 59.535 61.31
Property/Plant/Equipment, Total - Gross 89.37 88.754 99.541 98.995 98.885
Accumulated Depreciation, Total -33.641 -32.038 -41.565 -39.46 -37.575
Goodwill, Net 106.225 106.287 106.285 106.251 106.069
Intangibles, Net 4.274 7.242 10.21 13.178 16.145
Other Long Term Assets, Total 2.316 2.512 2.255 2.531 2.374
Total Current Liabilities 51.8 46.84 43.787 43.443 46.169
Accounts Payable 7.327 6.089 6.109 7.914 9.305
Accrued Expenses 24.602 20.853 19.072 19.01 21.053
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 14.871 15.315 15.273 14.436 14.978
Total Liabilities 159.752 157.961 157.554 160.524 166.409
Total Long Term Debt 59.59 60.662 61.734 62.809 63.885
Long Term Debt 59.59 60.662 61.734 62.809 63.885
Deferred Income Tax 1.017 1.049 1.052 1.055 0.62
Other Liabilities, Total 47.345 49.41 50.981 53.217 55.735
Total Equity 179.533 197.866 214.1 229.786 248.506
Preferred Stock - Non Redeemable, Net
Common Stock 0.082 0.081 0.08 0.08 0.079
Additional Paid-In Capital 856.926 853.466 850.063 847.008 845.034
Retained Earnings (Accumulated Deficit) -980.976 -959.979 -942.939 -926.096 -905.251
Unrealized Gain (Loss) -0.502 -0.949
Other Equity, Total -1.949 -1.551 -1.328 -1.394 -1.66
Total Liabilities & Shareholders’ Equity 339.285 355.827 371.654 390.31 414.915
Total Common Shares Outstanding 79.47 79.121 78.652 79.482 79.246
Current Port. of LT Debt/Capital Leases 5 4.583 3.333 2.083 0.833
Short Term Investments 49.195 0 40.874 84.475 124.968
Redeemable Preferred Stock 311.253 311.253 311.253 311.253 311.253
Treasury Stock - Common -5.803 -5.404 -3.029 -0.563
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -190.098 -59.237 -53.02 -64.79 -59.013
Cash From Operating Activities -89.37 -44.061 -15.417 -35.21 -25.201
Cash From Operating Activities 3.499 3.653 4.014 4.605 5.372
Amortization 11.528 11.918 11.91 11.2 11.2
Non-Cash Items 101.183 19.538 19.265 27.014 19.718
Cash Taxes Paid 0.309 2.085 0.521 0.205 0.321
Cash Interest Paid 3.493 3.149 3.089 3.542 5.534
Changes in Working Capital -15.482 -19.933 2.414 -13.239 -2.478
Cash From Investing Activities -88.127 -11.946 39.975 -39.301 4.719
Capital Expenditures -3.825 -13.264 -12.717 -2.531 -0.372
Other Investing Cash Flow Items, Total -84.302 1.318 52.692 -36.77 5.091
Cash From Financing Activities 230.758 15.959 20.857 2.79 57.66
Financing Cash Flow Items -12.758 -1.872 -1.143 -2.517 -3.22
Issuance (Retirement) of Stock, Net 225.354 1.494 22 2.133 60.88
Foreign Exchange Effects -0.404 -0.021 0.385 0.056 0.167
Net Change in Cash 52.857 -40.069 45.8 -71.665 37.345
Issuance (Retirement) of Debt, Net 18.162 16.337 0 3.174
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -16.843 -190.098 -169.253 -139.827 -76.288
Cash From Operating Activities -8.485 -89.37 -70.189 -45.578 -15.59
Cash From Operating Activities 0.862 3.499 2.68 1.878 1.003
Amortization 2.8 11.528 8.728 5.928 2.968
Non-Cash Items 3.038 101.183 98.557 91.227 53.655
Cash Taxes Paid 0.306 0.309 0.248 0.638 0.488
Cash Interest Paid 0.232 3.493 1.847 1.679 0.102
Changes in Working Capital 1.658 -15.482 -10.901 -4.784 3.072
Cash From Investing Activities 43.154 -88.127 -128.372 -139.108 -0.868
Capital Expenditures -1.01 -3.825 -3.07 -1.806 -0.868
Other Investing Cash Flow Items, Total 44.164 -84.302 -125.302 -137.302 0
Cash From Financing Activities -2.558 230.758 231.028 231.033 18.075
Financing Cash Flow Items -12.758 -12.728 -12.724
Issuance (Retirement) of Debt, Net 0 18.162 18.162 18.162 18.162
Foreign Exchange Effects 0.023 -0.404 -0.719 -0.437 -0.085
Net Change in Cash 32.134 52.857 31.748 45.91 1.532
Issuance (Retirement) of Stock, Net -2.558 225.354 225.594 225.595 -0.087
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Caligan Partners, LP Hedge Fund 9.8118 7797454 -670466 2023-07-03
Indaba Capital Management, L.P. Hedge Fund 9.3699 7446229 0 2023-06-30 MED
Neuberger Berman, LLC Investment Advisor/Hedge Fund 5.669 4505149 -3627 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.9615 3942890 -13078 2023-06-30 LOW
PRIMECAP Management Company Investment Advisor 4.053 3220917 -1276656 2023-06-30
Morgan Stanley Investment Management Inc. (US) Investment Advisor/Hedge Fund 3.7879 3010227 -102421 2023-06-30 LOW
North Sound Management, LLC Investment Advisor 3.0155 2396400 -1978600 2022-12-31
Boothbay Fund Management, LLC Investment Advisor/Hedge Fund 2.897 2302278 0 2023-06-30 HIGH
Balyasny Asset Management LP Hedge Fund 2.6446 2101690 2101690 2023-06-30 HIGH
Needham Investment Management L.L.C. Investment Advisor/Hedge Fund 2.56 2034435 -835565 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 1.771 1407437 16275 2023-06-30 LOW
MFP Investors, LLC Investment Advisor 1.2333 980100 7346 2023-06-30 MED
Hightower Advisors, LLC Investment Advisor 0.9894 786286 -206233 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.8657 687946 -26101 2023-06-30 LOW
Renaissance Technologies LLC Hedge Fund 0.7869 625309 289009 2023-06-30 HIGH
Millennium Management LLC Hedge Fund 0.7377 586267 -325844 2023-06-30 HIGH
Azimut Capital Management Sgr SpA Investment Advisor/Hedge Fund 0.6761 537259 0 2023-09-30 HIGH
Silverback Asset Management, LLC Hedge Fund 0.5663 450000 50000 2023-06-30
D. E. Shaw & Co., L.P. Hedge Fund 0.4325 343697 -236806 2023-06-30 MED
Burbach (Gerhard F) Individual Investor 0.4312 342653 290370 2023-04-18 MED

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Standard BioTools Inc Company profile

About Fluidigm Corporation

Fluidigm Corporation creates, manufactures, and markets a range of products and services, including instruments, consumables, reagents, and software that are used by researchers and clinical labs. The Company operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. It markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits (ifcs), assays, and reagents. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Fluidigm Corporation revenues decreased 5% to $130.6M. Net loss increased 12% to $59.2M. Revenues reflect Development revenue segment decrease of 71% to $2.6M, Instruments segment decrease of 7% to $42.5M, United States segment decrease of 16% to $60.2M, Asia-Pacific segment decrease of 7% to $24M. Higher net loss reflects Research and development increase of 4% to $37.9M (expense), Selling.

Equity composition

Common Stock $0.001 Par, 2/11, 19,938,754 auth, 19,938,754 issd. Insiders own approx. 11.14%.

Industry: Advanced Medical Equipment & Technology (NEC)

2 Tower Place
Suite 2000
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

US100

17,914.30 Price
-0.300% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 22:00 (UTC)
Spread 7.0

XRP/USD

0.55 Price
-0.270% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

BTC/USD

51,701.35 Price
+0.170% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Oil - Crude

76.56 Price
-2.240% 1D Chg, %
Long position overnight fee 0.0163%
Short position overnight fee -0.0382%
Overnight fee time 22:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading